- Home
- NVOS vs LSBPW Comparison
NVOS vs LSBPW Comparison
Compare NVOS & LSBPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVOS
- LSBPW
- Stock Information
- Founded
- NVOS 2000
- LSBPW N/A
- Country
- NVOS United States
- LSBPW China
- Employees
- NVOS N/A
- LSBPW 758
- Industry
- NVOS Assisted Living Services
- LSBPW Biotechnology: Pharmaceutical Preparations
- Sector
- NVOS Health Care
- LSBPW Health Care
- Exchange
- NVOS Nasdaq
- LSBPW Nasdaq
- Market Cap
- NVOS 5.6M
- LSBPW N/A
- IPO Year
- NVOS 2017
- LSBPW N/A
- Fundamental
- Price
- NVOS $0.23
- LSBPW $0.07
- Analyst Decision
- NVOS
- LSBPW
- Analyst Count
- NVOS 0
- LSBPW 0
- Target Price
- NVOS N/A
- LSBPW N/A
- AVG Volume (30 Days)
- NVOS 326.8K
- LSBPW N/A
- Earning Date
- NVOS 12-12-2024
- LSBPW N/A
- Dividend Yield
- NVOS N/A
- LSBPW N/A
- EPS Growth
- NVOS N/A
- LSBPW N/A
- EPS
- NVOS N/A
- LSBPW N/A
- Revenue
- NVOS $13,516,958.00
- LSBPW N/A
- Revenue This Year
- NVOS N/A
- LSBPW N/A
- Revenue Next Year
- NVOS N/A
- LSBPW N/A
- P/E Ratio
- NVOS N/A
- LSBPW N/A
- Revenue Growth
- NVOS 1102.98
- LSBPW N/A
- 52 Week Low
- NVOS $0.20
- LSBPW N/A
- 52 Week High
- NVOS $3.45
- LSBPW N/A
- Technical
- Relative Strength Index (RSI)
- NVOS 38.13
- LSBPW N/A
- Support Level
- NVOS $0.20
- LSBPW N/A
- Resistance Level
- NVOS $0.31
- LSBPW N/A
- Average True Range (ATR)
- NVOS 0.03
- LSBPW 0.00
- MACD
- NVOS 0.00
- LSBPW 0.00
- Stochastic Oscillator
- NVOS 27.18
- LSBPW 0.00
About NVOS Novo Integrated Sciences Inc.
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.
About LSBPW LakeShore Biopharma Co. Ltd
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.